Fezolinetant + Placebo
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Trial Timeline
Dec 5, 2025 → Mar 1, 2028
NCT ID
NCT06917313About Fezolinetant + Placebo
Fezolinetant + Placebo is a phase 2 stage product being developed by Astellas Pharma for Breast Cancer Early Stage Breast Cancer (Stage 1-3). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06917313. Target conditions include Breast Cancer Early Stage Breast Cancer (Stage 1-3).
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer Early Stage Breast Cancer (Stage 1-3) were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06917313 | Phase 2 | Recruiting |
| NCT06812754 | Phase 2 | Completed |
| NCT06206421 | Phase 3 | Active |
| NCT06206408 | Phase 3 | Completed |
| NCT05034042 | Phase 2 | Completed |
| NCT05033886 | Phase 3 | Completed |
| NCT04234204 | Phase 3 | Completed |
| NCT04003155 | Phase 3 | Completed |
| NCT04003142 | Phase 3 | Completed |
| NCT04003389 | Phase 3 | Completed |
| NCT03192176 | Phase 2 | Completed |
| NCT05419908 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer Early Stage Breast Cancer (Stage 1-3)